

PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS

PGxOne™ Plus is a pharmacogenomics test that can help predict how a patient will respond to drug therapy based on individual genetic makeup.

- · Genetic variants affect drug absorption, metabolism and activity. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing.
- Provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac and pain medications
- Cutting-edge Next Generation Sequencing (NGS) technology enables comprehensive coverage of ~200 genetic variants in 50 genes.
- · Delivers medically actionable recommendations in an easy to interpret report.

Selected Covered Drug Classes from Major Therapeutic Areas

Cardiology

ACE Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Antianginal Agent

Antiarrhythmic Agent

Anticoagulant

Antiplatelet

Beta Blockers

Calcium Channel Blockers

Diuretics

Phosphodiesterase Inhibitors

Antilipemic Agent(statins)

Vasodilators

Infectious Diseases

Antibiotics Antimalarial Drugs Antiviral Drugs Protease Inhibitors

Psychiatry

Aldehyde Dehydrogenase Inhibitors

Antimanic Agents

Antipsychotics

Benzodiazepines

Tricyclic Antidepressants

Cannabinoids

Stimulants

Antianxiety Agents

Antidepressants

SNRIs

SSRIs

Neurology

Anticonvulsant Drugs

Barbiturates

COMT Inhibitors

Monoamine Depletors

Antimigraine Agent

Pain Management

Anesthetics

Central α-2 Adrenergic Agonists

Alpha2-Adrenergic Agonist

NSAIDs

Opioids

Opioids Antagonists

Serotonin Receptor Agonists

Skeletal Muscle Relaxant

Oncology

Taxane Derivative

Antimetabolite

Platinum Analog

Alkylating Agent

Anthracycline

Chemotherapy Modulating Agent

Urate-Oxidase

Estrogen Receptor Modulator

Kinase Inhibitor

Antiemetic Topoisomerase Inhibitors

Immunomodulators

Vinca Alkaloids

Associated drugs carry pharmacogenomics recommendations put forth by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and/or related pharmacogenemics publications.








Genes

Target Genes and Select Therapeutic Areas



*PGxOne™ Plus is the most comprehensive, commercially available pharmacogenomics test covering more genes than competitors

